Market revenue in 2023 | USD 330.5 million |
Market revenue in 2030 | USD 1,836.7 million |
Growth rate | 27.8% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Therapeutics |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Therapeutics, Diagnostics |
Key market players worldwide | Novartis AG ADR, Oncopeptides AB, Bicycle Therapeutics PLC ADR, AstraZeneca PLC, Theratechnologies Inc, Cybrexa Therapeutics, AngioChem, Soricimed |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to peptide drug conjugates market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.48% in 2023. Horizon Databook has segmented the North America peptide drug conjugates market based on therapeutics, diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America peptide drug conjugates market , including forecasts for subscribers. This continent databook contains high-level insights into North America peptide drug conjugates market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account